NewsFlash »

ASH 2009 Conference Prompts Doctors To Change Myeloma Treatment Practices, Study Finds – A study conducted by Majestic Marketing Research Group discovered that 43 percent of doctors surveyed intend to change their multiple myeloma treatment practices based on results presented at the American Society of Hematology’s 2009 meeting. Most of these changes will increase use of either Velcade (bortezomib) or Revlimid (lenalidomide). The MM-015 study evaluating a Revlimid combination (see related Beacon news) left a particularly strong impression on the majority of doctors surveyed. For more information, please see the Majestic Research press release.

Sagent Pharma Launches Generic Alternative to Aredia – Sagent Pharma announced the launch of a generic alternative to Aredia (pamidronate disodium), a treatment for cancer-related osteoporosis marketed by Novartis Pharma. The injection will come in single-dose vials of 30 mg/10 mL and 90 mg/10 mL. For more information, please see the Sagent Pharma press release.

Terpenoid Therapeutics Raises $950,000 For Myeloma-Related Drug Development – Terpenoid Therapeutics has raised $950,000 of its intended $1.05 million for the development of two cancer drugs, one of which will treat bone disease associated with cancers such as multiple myeloma. Researchers anticipate the drug will cause fewer side effects than current treatment options. For more information, please visit the MedCity News Web site.